Isis Pharmaceuticals (ISIS -5.5%) says it's earned a $10M milestone payment from AstraZeneca's...

|By:, SA News Editor

Isis Pharmaceuticals (ISIS -5.5%) says it's earned a $10M milestone payment from AstraZeneca's (AZN) decision to add a second development candidate to their collaboration on cancer antisense drugs. ISIS had struck the deal in December to develop therapeutics against five cancer targets, including an exclusive license for AZN to develop ISIS-STAT3, a drug ISIS was evaluating for treating advanced lymphoma. It's now adding a second development candidate, ISIS-AR(Rx), to the collaboration.